Abstract Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL), representing approximately 25-30% of newly diagnosed adult NHL in Western countries. CD5-positive DLBCL has been reported in 10% of cases in some series. DLBCL with cyclin D1 expression has also been reported in the literature. These cases may sometimes be confused with mantle cell lymphoma (MCL), especially blastoid variant MCL, morphologically and immunophenotypically. Herein, we present an unusual case of a 41-year-old female without significant medical history who presented with a right facial/parotid mass. Morphologically, the tumor showed a diffuse growth pattern of large lymphoid cells with vesicular nuclei, consistent with a DLBCL. Immunostains, however, showed that the tumor cells were positive for both CD5 and cyclin D1. Fluorescence in situ hybridization studies showed a rearrangement of the Bcl-6 gene (3q27) in 29.5% of cells but no evidence of 14)] or IgH/Bcl-2 [t(14;18)] rearrangement. Immunostain for SOX11 was also performed and is negative. The clinicopathologic features of this CD5-and cyclin D1-positive DLBCL are described, and the differential diagnosis between DLBCL and MCL is discussed.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) and accounts for approximately 25-30% of new diagnoses of adult NHL in Western countries [1] . Morphologically, the tumors typically demonstrate a diffuse proliferation pattern and consist of large cells with vesicular nuclei, prominent nucleoli, and abundant cytoplasm. Immunophenotypically, the tumor cells are positive for CD20 but negative for CD3. Bcl-6 is estimated to be positive in 60-90% of cases and MUM1 in 35-65% of cases. The reported frequency of CD10 varies from 30-60% and is associated with the germinal center subtype (GCB-DLBCL). Aberrant CD5 expression has been reported in up to 10% of cases [1, 2] . Cyclin D1 expression has been associated with only 12 reported cases of DLBCL in the literature [3] [4] [5] . Cytogenetically, the Bcl-6 gene (3q27) rearrangement is the most common abnormality in DLBCL [1] .
Mantle cell lymphoma (MCL) comprises 3-10% of NHL and is typically composed of monomorphic small to medium-sized lymphoid cells with irregular nuclear contours and inconspicuous nucleoli [6] . The tumor cells in almost all MCL cases are positive for cyclin D1, and many are positive for CD5. SOX11 is a new biomarker that has been shown to be highly specific for MCL, as it is detected in 93% of cyclin D1-positive cases [7, 8] . Lambda light chain restriction is more frequently seen in MCL, and MCL cells typically show moderate to strong intensity of surface immunoglobulin [6, 9] . MCL typically demonstrates a t(11;14) translocation, and rearrangements of the BCL-6 gene only rarely occur in MCL [10] . The rare cases of MCL that are negative for cyclin D1 and lack the t(11;14) have an expression profile that is otherwise indistinguishable from conventional MCL and express SOX11 [9] . Blastoid MCL is characterized by increased nuclear size, pleomorphism, and increased mitotic activity and is typically cyclin D1 and CD5 positive, but aberrant expression of CD10 and loss of CD5 have also been described [6] .
Herein, we present an unusual case of DLBCL that is positive for both CD5 and cyclin D1. The diagnosis of DLBCL is supported by large centroblastic morphology, immunoreactivity of Bcl-6 and MUM1, negativity for SOX11, and lack of the t(11;14) translocation. 
Case report
The patient is a 41-year-old female without a significant past medical history who initially presented with a right facial mass. The patient attributed this to an upper respiratory illness until several months later when she noticed an increased size of the mass. Upon examination a 3.0×2.0-cm right facial nodule was noted within the parotid tail. The lesion was firm and tender to palpation. Right cervical lymphadenopathy was also present. The right parotid tail and right jugular lymph nodes were excised, and sections demonstrated atypical medium-to large-sized lymphoid cells with moderate amount of cytoplasm, vesicular chromatin, and variably prominent nucleoli. The tumor cells proliferated in a diffuse pattern that obliterated normal nodal architecture. Numerous epithelioid histiocytes were also present (Fig. 1a, b) . Flow cytometry of the parotid mass showed a CD5-positive mature B-cell population expressing CD19, CD20, CD22, CD38, and FMC7, with low-density surface kappa light chain expression. Immunohistochemical stains show that the tumor cells were positive for CD20 (Fig. 1c) , but negative for CD3 (Fig. 1d) . The cells were also weakly positive for CD5 (Fig. 1d inset) . Cyclin D1 positivity was seen in approximately 30% of neoplastic cells with heterogeneous reactivity. A cyclin D1/ CD20 dual stain specifically demonstrated positivity for cyclin D1 in the neoplastic B cells (Fig. 1e) . Additionally, the tumor cells were positive for CD43, Bcl-2, Bcl-6 (Fig. 1g) , and MUM1 (Fig. 1h) , but negative for CD10 and SOX11 (Fig. 1f) . Fluorescence in situ hybridization (FISH) studies showed a rearrangement of the Bcl-6 gene (3q27) 
Discussion
Herein, we report a case of DLBCL with aberrant expression of both CD5 and cyclin D1. The diagnosis of DLBCL was supported by combined clinical, morphological, immunophenotypic, and molecular cytogenetics findings. It is important to recognize that this case could be easily confused with a blastoid MCL due to aberrant expression of cyclin D1 and CD5. The relatively young age, female gender, and localized disease favor a diagnosis of DLBCL over MCL clinically. Centroblastic morphology, strong expression of BCL-6 and MUM1, and dim kappa expression support the diagnosis of DLBCL. The heterogeneous expression of cyclin D1 also favors a DLBCL. In cyclin D1-positive MCL, the staining pattern is expected to be strong, uniform, and in greater than 90% of tumor cells. In cyclin D1-negative MCL, the staining pattern is expected to be entirely negative. In our case, approximately 30% of cells are positive for cyclin D1 and show marked [3] [4] [5] . FISH studies demonstrated absence of the t(11;14) translocation in 11 of the 12 cases. The remaining case (case 4) which was positive for the t (11;14) , and showed strong cyclin D1 positivity, may have been a misdiagnosed MCL [11] . In the t(11;14)-negative cases, cyclin D1 expression ranged from <30% to 60% of the tumor cells. All 12 cases were negative for CD5. Ehinger found that 10 (4.3%) of 231 cases of DLBCL cases were positive for cyclin D1 and none were positive for CD5. Rodriguez-Justo and Teruya-Feldstein each presented a case of cyclin D1-positive DLBCL [3, 4] . Comparison of these 12 cases show that, excluding the misdiagnosed MCL, either Bcl-6 or MUM1 was expressed [2] . These cases illustrate how cyclin D1-positive DLBCL may best be differentiated from MCL. Blastoid MCL is most likely to be confused with DLBCL due to large nuclear size and lack of CD5 expression. As previously discussed, Bcl-6 and MUM1 positivity suggest DLBCL, while the presence of t(11;14) is consistent with MCL [5] . Zhang et al. have also reported five cases of CD5 and cyclin D1 positive DLBCL and concluded that these were transformed from MCL; however, analysis for t(11;14) was not performed [11] . Since our case shows no evidence of the t(11;14), a transformation from MCL is unlikely.
There are multiple reported cases of CD5-positive DLBCL in the literature, and it is actually estimated that 10% of cases of DLBCL will be positive for CD5 [1, 2, 12, 13] . CD5-positive DLBCL are typically distinguished from MCL by morphology and lack of cyclin D1 expression.
In conclusion, CD5-positive and cyclin D1-positive DLBCLs do exist. The patient's age, female gender, morphologic features, variable staining for cyclin D1, positivity for BCL-6 and/or MUM1, negativity for SOX11, and the lack of t(11;14) help to differentiate these cases from a blastoid MCL. The presence of Bcl-6 (3q27) rearrangements would further support a diagnosis of DLBCL instead of blastoid MCL.
